Google
Trusted Resources: News & Meetings
Latest announcements and gatherings
AstraZeneca advances scientific leadership in haematology at ASH 2023
myBinder
Alnylam Announces Receipt of Complete Response Letter from U.S. FDA for Supplemental New Drug Application for Patisiran for the Treatment of the Cardiomyopathy of ATTR Amyloidosis
myBinder
Alnylam Announces Positive Outcome of FDA Advisory Committee Meeting
myBinder
Acoramidis Reduces All-Cause, Cardiovascular Mortality at 30 Months in ATTR-CM
myBinder
Eplontersen halted ATTRv-PN disease progression and improved neuropathy impairment and quality of life in Phase 3 study through 66 weeks
myBinder
India’s first Amyloid Center inaugurated at Amrita Hospital
myBinder
oneAMYLOIDOSISvoice.com Support Group Platform Begins Empowering the Amyloidosis Community With Invaluable Info About Amyloidosis
myBinder
HealthWell Foundation Opens New Amyloidosis Fund to Assist Patients With Treatment Costs
myBinder
SCMR Partners With Foundation to Promote March as Amyloidosis Awareness Month
myBinder
Alexion Pharmaceuticals Partners With Caelum Biosciences to Tackle Light Chain Amyloidosis
myBinder
Hereditary amyloidosis in Brazil: a focus on access to diagnosis and treatment
myBinder
Amyloidosis, A Tricky Diagnosis, Can Be Traced to Vietnam and Exposure to Agent Orange
myBinder
With CRISPR Gene Editing, Unique Treatments Begin to Take off for Rare Diseases
myBinder
He Inherited A Devastating Disease. A CRISPR Gene-Editing Breakthrough Stopped It
myBinder
A vision toward a more holistic approach to care in hereditary ATTR amyloidosis
myBinder
Amyloidosis now a hot topic in cardiac imaging due to new drug treatment
myBinder
Ultromics granted FDA Breakthrough Device Designation for AI-enhanced Cardiac Amyloidosis detection
myBinder
Ionis announces FDA acceptance of New Drug Application for eplontersen for the treatment of hereditary transthyretin-mediated amyloid polyneuropathy (ATTRv-PN)
myBinder
The Orphan Drug Act Turns 40: NORD Celebrates Its Impact on Rare Diseases
myBinder
2nd Annual Bradley Z. Naifeh Amyloidosis Conference
myBinder
Hereditary ATTR (hATTR) Amyloidosis: Educational Overview
myBinder
Amyloidosis Foundation: Nashville Support Group Meeting
myBinder
ATTR-Wild Type and Hereditary Amyloidosis Support Group Meeting – LIVE – October 27-29, 2023
myBinder
CMAF Benefit Dinner: Evening of Corvettes, Dinner & Fun!
myBinderTo improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences.
More information
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.
Community Key Collaborator
Support for this landing page is provided by an independent education grant from
Translation of this platform made possible through an independent education grant from
Powered by
To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences.
More information
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.
